According to Genomeweb, Illumina had 66% of the market in 2012:
Roche's share was 8% at this point.
I think you may have been a bit misled on their market penetration post PGM and post-MiSeq
-
Why is any technology killed off? It's been superseded - either on price or performance or both.
According to Genomeweb, Illumina had 66% of the market in 2012:
Roche's share was 8% at this point.
I think you may have been a bit misled on their market penetration post PGM and post-MiSeq -
{Discussion}Roche stop supporting the 454 platform by mid-2016
Hi, I am a graduate student and I have just heard Roche stop supporting the 454 pyrosequencing platform by 2016. Our university has to buy another Next-gen sequencing platform.
I was surprised. Does anyone know what happened? Two year ago, I think 454 pyrosequencing occupied >50% market. I don't think this is about business. Also, lots of publications use pyrosequencing
Are they gonna develop new sequencing technologies? Is pyrosequencing a technological dead end? Is Illumina a good choice?
Ben
-
The field of epigenetics has traditionally concentrated more on DNA and how changes like methylation and phosphorylation of histones impact gene expression and regulation. However, our increased understanding of RNA modifications and their importance in cellular processes has led to a rise in epitranscriptomics research. “Epitranscriptomics brings together the concepts of epigenetics and gene expression,” explained Adrien Leger, PhD, Principal Research Scientist...04-22-2024, 07:01 AM -
Proteins are often described as the workhorses of the cell, and identifying their sequences is key to understanding their role in biological processes and disease. Currently, the most common technique used to determine protein sequences is mass spectrometry. While still a valuable tool, mass spectrometry faces several limitations and requires a highly experienced scientist familiar with the equipment to operate it. Additionally, other proteomic methods, like affinity assays, are constrained...04-04-2024, 04:25 PM
Leave a comment: